VJHemOnc is committed to improving our service to you

IMW 2019 | A.R.R.O.W. study: carfilzomib dosing in frail MM patients

VJHemOnc is committed to improving our service to you

Maria-Victoria Mateos

Maria-Victoria Mateos, MD, PhD from the University of Salamanca, Salamanca, Spain, gives an update on the Phase III A.R.R.O.W. study (NCT02412878) looking at carfilzomib dosing in frail MM patients. Dr Mateos was speaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter